EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Signs Agreement With Boudicca Dx To Advance Regulatory Strategy For Companion Diagnostics Genetic Test For AD04
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has signed an agreement with Boudicca Dx to advance the regulatory strategy for a companion diagnostics genetic test for AD04.
August 13, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has entered into a partnership with Boudicca Dx to enhance the regulatory strategy for a companion diagnostics genetic test for AD04.
The partnership with Boudicca Dx is a strategic move to advance the regulatory approval process for AD04, which could potentially accelerate the product's market entry and boost investor confidence in Adial Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100